Conflicts of interest: None.

DHT

:   dihydrotestosterone

PTHrP

:   parathyroid hormone‐related protein

ER

:   estrogen receptor

AR

:   androgen receptor

NR

:   nuclear receptor

PSA

:   prostate cancer antigen

wt

:   wild‐type

E2

:   17β‐estradiol

HHM

:   humoral hypercalcemia of malignancy

PR

:   progesterone receptor

atRA

:   all‐trans retinoic acid

qRT‐PCR

:   quantitative real‐time PCR

GAPDH

:   glyceraldehyde‐3‐phosphate dehydrogenase

siCT

:   control siRNA

ARE

:   AR response element

GR

:   glucocorticoid receptor

Dex

:   dexamethasone, TSA, trichostatin A

Estrogen and androgen are key regulators of sex steroid‐dependent cancers. The conventional view is that most breast cancers depend on estrogen‐estrogen receptor (ER)α signaling for their development and proliferation, while prostate cancers rely largely on the androgen‐androgen receptor (AR) axis.

Breast cancer is commonly associated with humoral hypercalcemia of malignancy (HHM) (Hickey et al., [1981](#jcp24906-bib-0022){ref-type="ref"}) due to ectopic production of parathyroid hormone‐related protein (PTHrP) by cancer tissues and its systemic action on bone and kidney (Mundy and Edwards, [2008](#jcp24906-bib-0041){ref-type="ref"}). Local production of PTHrP in osseous tissues following bone metastasis of primary breast cancer also contributes to deleterious development of hypercalcemia and aggressive bony destruction (Chirgwin and Guise, [2000](#jcp24906-bib-0008){ref-type="ref"}). On the other hand, prostate cancer is less commonly associated with HHM and local osteolytic lesions. Nonetheless, PTHrP is crucially involved in enhancing cancer cell proliferation, survival, and migration (Dougherty et al., [1999](#jcp24906-bib-0010){ref-type="ref"}; Asadi and Kukreja, [2005](#jcp24906-bib-0003){ref-type="ref"}). As such, it is important to understand the regulatory mechanism of the *PTHrP* gene, and several intriguing signal molecules have been postulated to stimulate *PTHrP* expression in breast and prostate cancers (Lindemann et al., [2001](#jcp24906-bib-0032){ref-type="ref"}; Lindemann et al., [2003](#jcp24906-bib-0033){ref-type="ref"}; Sterling et al., [2006](#jcp24906-bib-0053){ref-type="ref"}; Gilmore et al., [2008](#jcp24906-bib-0018){ref-type="ref"}).

Recently, we and others reported that expression of the *PTHrP* gene is commonly repressed by several steroid hormones including estrogens (Rabbani et al., [2005](#jcp24906-bib-0047){ref-type="ref"}), androgens (Pizzi et al., [2003](#jcp24906-bib-0046){ref-type="ref"}), 1,25‐dihydroxyvitamin D3 (Ikeda et al., [1989](#jcp24906-bib-0024){ref-type="ref"}; Inoue et al., [1993](#jcp24906-bib-0025){ref-type="ref"}; Endo et al., [1994](#jcp24906-bib-0012){ref-type="ref"}; Falzon, [1996](#jcp24906-bib-0013){ref-type="ref"}; Nishishita et al., [1998](#jcp24906-bib-0043){ref-type="ref"}; Okazaki et al., [2003](#jcp24906-bib-0044){ref-type="ref"}), glucocorticoids (Lu et al., [1989](#jcp24906-bib-0035){ref-type="ref"}; Kasono et al., [1991](#jcp24906-bib-0028){ref-type="ref"}; Liu et al., [1993](#jcp24906-bib-0034){ref-type="ref"}; Glatz et al., [1994](#jcp24906-bib-0019){ref-type="ref"}; Rizzoli et al., [1994](#jcp24906-bib-0048){ref-type="ref"}; Walsh et al., [1995](#jcp24906-bib-0060){ref-type="ref"}; Ahlstrom et al., [2009](#jcp24906-bib-0001){ref-type="ref"}), and progesterone (Sugimoto et al., [1999](#jcp24906-bib-0054){ref-type="ref"}; Kurebayashi et al., [2003](#jcp24906-bib-0029){ref-type="ref"}). To comprehensively explore these repression processes, we systematically surveyed several cell lines and characterized *PTHrP* gene regulation in response to a series of steroid hormones mediated by their cognate nuclear receptors (NRs). In our previous report, we described suppression of the *PTHrP* gene by complexes of administered steroid hormones and their cognate NRs in common, with the exception of the dihydrotestosterone (DHT)‐AR partnership in human breast cancer MCF‐7 cells. Interestingly, DHT repressed *PTHrP* gene expression through ERα, but not the endogenous and functional AR in these cells (Kajitani et al., [2011](#jcp24906-bib-0026){ref-type="ref"}).

In this study, we found that such a distorted ligand‐NR interaction is also present in another steroid hormone‐dependent cell line, namely, human prostate cancer LNCaP cells, by examining the repression of *PTHrP* and the activation of the *prostate‐specific antigen* (*PSA*) genes. It is known that the AR in LNCaP cells has a point mutation (Thr‐Ala877) in its ligand‐binding domain (LBD) (Buchanan et al., [2001](#jcp24906-bib-0006){ref-type="ref"}) that results in the partial loss of the AR\'s ligand specificity and cross‐reaction with several ligands, including estrogen, pregnenolone, progesterone, and steroidal compounds such as antiandrogens (Veldscholte et al., [1992](#jcp24906-bib-0059){ref-type="ref"}; Grigoryev et al., [2000](#jcp24906-bib-0020){ref-type="ref"}). AR (Thr‐Ala877)‐expressing LNCaP was originally established from a metastatic lesion of human prostatic adenocarcinoma (Horoszewicz et al., [1980](#jcp24906-bib-0023){ref-type="ref"}) and there are several reports describing AR (Thr‐Ala877) is expressed in clinical prostate cancers (Suzuki et al., [1993](#jcp24906-bib-0056){ref-type="ref"}; Gaddipati et al., [1994](#jcp24906-bib-0016){ref-type="ref"}; Suzuki et al., [1996](#jcp24906-bib-0055){ref-type="ref"}; Taplin et al., [2003](#jcp24906-bib-0058){ref-type="ref"}; Ceraline et al., [2004](#jcp24906-bib-0007){ref-type="ref"}).

First, we quantified the expression of the *AR, ERα, ERβ*, and *progesterone receptor* (*PR*) genes. After performing quantitative real‐time (qRT)‐PCR to examine transcriptional regulation of the *PTHrP* and *PSA* genes by several steroid hormones, we investigated the knockdown effect of several *NRs* on gene expression in LNCaP cells. Then, we carried out microarray experiments to explore whether or not hormonal cross‐reactivity mediated by the AR (Thr‐Ala877) was widespread in these cells. To determine whether the aberrant ligand‐NR interaction in the LNCaP cells was a direct consequence of this AR mutation, we next employed AR (wild‐type \[wt\]) and AR (Thr‐Ala877) expression‐based reporter assays to determine whether or not this AR mutation leads to the distorted ligand‐NR interaction. Finally, we examined the AR nuclear translocation in response to these hormones by confocal immunofluorescence microscopy.

Materials and Methods {#jcp24906-sec-0003}
=====================

Cell cultures and hormones {#jcp24906-sec-0004}
--------------------------

Prostate cancer LNCaP cells and Rv22 cells, gifts from Dr. Shigeo Horie (Department of Urology, Teikyo Medical School, Japan), and breast cancer MCF‐7 cells, T47D cells, and MDA‐MB‐453 cells, kindly provided by Dr. Shunji Takahashi (Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Japan), were maintained in monolayer cultures in RPMI‐1640 phenol red free medium (Life Technologies, Carlsbad, CA) supplemented with 5% (v/v) fetal bovine serum and antibiotics (Life Technologies) in humidified 5% CO~2~--95% air at 37°C. The following chemicals were obtained from commercial sources: 17β‐estradiol (E2) (Wako Pure Chemical, Osaka, Japan), DHT (Sigma Aldrich, St. Louis, MO), all‐trans retinoic acid (atRA) (Sigma Aldrich), R5020 (Thermo Fisher Scientific, Waltham, MA), TSA (Sigma Aldrich), and MDV3100 (Selleckchem, Houston, TX). At 24 h before hormone treatment, serum‐free media were used, and the cells were exposed to the indicated hormones with serum‐free media for another 24 h. As shown in Supplemental Fig. 1, the use of these serum‐free media minimally affected the cell growth and the cell number, indicating intensive apoptosis did not occur. Forty‐eight to 72 h serum starvation for examining the hormonal effect in LNCaP cells has been employed by others (Perry and Tindall, [1996](#jcp24906-bib-0045){ref-type="ref"}; Shanmugam et al., [2007](#jcp24906-bib-0052){ref-type="ref"}).

The ligand concentration was 2.0 × 10^−9^ M, 2.0 × 10^−8^ M, and 2.0 × 10^−7^ M, respectively. MDV3100, TSA and atRA were dissolved in DMSO, and the others in ethanol.

siRNA transfection {#jcp24906-sec-0005}
------------------

Control siRNA and mixtures of siRNAs for the *ERα, ERβ, AR*, and *PR* genes were obtained from Dharmacon (Thermo Fisher Scientific). Forward transfection of siRNA was performed with LipofectamineRNAiMAX (Life Technologies) according to the manufacturer\'s instructions.

Quantitative real‐time PCR {#jcp24906-sec-0006}
--------------------------

qRT‐PCR was performed as described previously (Kajitani et al., [2011](#jcp24906-bib-0026){ref-type="ref"}). Relative gene expression was evaluated by the ΔCT method. The primer sets used in this study are shown in Supplemental Table 1. Data are normalized to glyceraldehyde‐3‐phosphate dehydrogenase (*GAPDH*) expression and presented relative to the vehicle (%). Values are expressed as means ± SD (n = 4, unless otherwise stated).

Western blotting {#jcp24906-sec-0007}
----------------

Cells were dissolved in SDS buffer containing 62.5 mM Tris‐HCl (pH 6.8), 2% SDS, 10% glycerol, and 100 mM dithiothreitol for whole cell protein preparation. For further cell fractionation, cells were suspended in buffer A (50 mM Hepes pH7.4, 0.1% Traiton‐X100, 10 mM NaCl, 20% glycerol, 1 mM EDTA, 2 mM EGTA, 2 mM MgCl~2~, 1 mM DTT, 1 mM NaVO4, 10 mM NaF and protease inhibitors (Roche, Basel, Switzerland). After incubation on ice for 20 min, lysates were centrifuged at 500 g for 3 min. Pellets were washed with buffer A and stored as nuclear pellets. The supernatants were stored as cytoplasmic fraction. The cytoplasmic fraction and the nuclear pellets were dissolved in SDS buffer and used as cytoplasmic protein and nuclear protein, respectively. Each protein was separated on 7.5% SDS‐polyacrylamide gel, followed by blotting to a Hybond‐LFP polyvinylidene fluoride membrane (GE Healthcare, Inc., Piscataway, NJ). After washing in PBS containing 0.2% (v/v) Tween 20 (PBST), the membrane was incubated with blocking solution composed of 5% (w/v) skim milk in PBST for 1 h. The membrane was reacted with rabbit antibody against human AR (H‐280; Santa Cruz Biotechnology, Santa Cruz, CA) diluted at 1:1,000, rabbit antibody against human AR (C‐19; Santa Cruz Biotechnology) diluted at 1:100, rabbit antibody against human ERα (HC‐20; Santa Cruz Biotechnology) diluted at 1:500, rabbit antibody against human PR (C‐20; Santa Cruz Biotechnology) diluted at 1:500, rabbit antibody against mouse Pol II (N‐20; Santa Cruz Biotechnology) diluted at 1:100, goat antibody against human LAMIN A/C (N‐18; Santa Cruz Biotechnology) diluted at 1:2,000 or mouse monoclonal antibody against α‐tubulin (T5168; Sigma Aldrich) diluted at 1:10,000 in the blocking solution overnight at 4°C. After washing in PBST, the membrane was reacted for 1 h at room temperature in blocking solution containing goat anti‐rabbit or anti‐mouse IgG, or donkey anti‐goat IgG antibody conjugated with Cy5 (Jackson ImmunoResearch, West Grove, PA) diluted at 1:2,000. Then, the membrane was washed in PBST, and the immunoreacted proteins were visualized using Typhoon (GE Healthcare).

Immunocytochemistry {#jcp24906-sec-0008}
-------------------

LNCaP cells were fixed with 4% paraformaldehyde in PBS for 20 min. The primary antibody was rabbit polyclonal antibody against human AR (H‐280) diluted 1:2,000 in PBST overnight. After washing in PBS, cells were incubated with a secondary antibody, Alexa 546‐labeled anti‐mouse goat IgG (Molecular Probes, Eugene, OR) in PBST for 2 h. Cells were washed in PBS, and their nuclei were stained with DAPI (Life Technologies) followed by immunofluorescence microscopy. Fluorescent images were obtained using an A1 Confocal Microscope System (Nikon, Tokyo, Japan).

Microarray analysis {#jcp24906-sec-0009}
-------------------

cDNA microarray analysis was performed using an authorized custom analysis service provider (APRO Life Science, Tokushima, Japan). Total RNA from the LNCaP cells transfected with control siRNA (siCT) or siRNA for AR (siAR) followed by 10^−7^ M of DHT, E2, or R5020 exposure for another 24 h was isolated using an RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer\'s instructions. RNA samples were quantified using an ND‐1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE), and their quality was confirmed using an Experion System (Bio‐Rad Laboratories, Hercules, CA). The cRNA was amplified and labeled using a Low Input Quick Amp Labeling Kit (Agilent Technologies, Inc., Santa Clara, CA), followed by hybridization to a SurePrint G3 Human GE Microarray 8 × 60K v2 (Agilent Technologies, Inc.) according to the manufacturer\'s instructions. All hybridized microarray slides were scanned using an Agilent scanner. Relative hybridization intensities and background hybridization values were calculated using Agilent Feature Extraction Software (9.5.1.1). Raw signal intensities and flags for each probe were calculated from the hybridization intensities (gProcessedSignal) and spot information (e.g., gIsSaturated) according to the procedures recommended by Agilent (Flag criteria in GeneSpring Software: Absent (A), "Feature is neither positive or significant" or "Feature is not above background"; Marginal (M), "Feature is not uniform", "Feature is saturated", or "Feature is a population outlier"; and Present (P), other). In addition, the raw signal intensities were log~2~‐transformed and normalized using the quantile algorithm in the 'preprocessCore\' library package (Bolstad et al., [2003](#jcp24906-bib-0005){ref-type="ref"}) of the Bioconductor software (Gentleman et al., [2004](#jcp24906-bib-0017){ref-type="ref"}). GEO accession number is GSE58615. We selected the probes that call the 'P\' flag in the siCT‐vehicle sample. The signals of each probe on the microarray were expressed as the signal/median value divided by the median value of all probes. To identify up‐ or down‐regulated genes, we calculated ratios (non‐log scaled fold‐change) for comparisons between each vehicle and hormone treatment sample. Then, we selected hormone target genes mediated by the LNCaP AR by applying criteria satisfying (siCT) ≥5.0 and (siAR) 1.0--2.0 for gene activation or (siCT) ≤0.2 and (siAR) 0.75--1.0 for gene repression.

Plasmid construction and luciferase assay {#jcp24906-sec-0010}
-----------------------------------------

After confirming that the *AR* cDNA obtained from the LNCaP cells had only one mutation (Thr‐Ala877) as previously reported, it was ligated into the mammalian expression vector pcDNA3.1Zeo+ (pcDNA3.1, Life Technologies). We then separately introduced the mutant AR or wt AR expression vector (a gift from Dr. Sigeaki Kato, then at The University of Tokyo). As a reporter plasmid, three copies of the AR response element (ARE; GGAACAgtaTGTTCT) (Roche et al., [1992](#jcp24906-bib-0050){ref-type="ref"}) were ligated into the upstream region of the thymidine kinase promoter of the pGL4‐TK vector (Promega, Madison, WI). At 23 h after seeding approximately 2 × 10^4^ cells/100 μl/well onto 96‐well plates, the media were changed to serum‐free RPMI‐1640 with antibiotics for 1 h followed by the introduction of 50 ng DNA (20 ng ARE/pGL4‐TK, 10 ng of either AR expression vector, and 20 ng phRL‐TK (Promega)/0.3 μl FuGeneHD (Promega)/well) into the LNCaP, MDA‐MB‐453, Rv22, and MCF‐7 cells. After incubation for 24 h, the cells were treated with each steroid hormone for another 24 h, and luciferase activity was assayed using the Dual‐luciferase Reporter Assay System (Promega). Means ± SD were calculated after quadruplicate transfection.

Localization analysis by enhanced green fluorescent protein (EGFP)‐AR fusion protein {#jcp24906-sec-0011}
------------------------------------------------------------------------------------

To produce EGFP‐AR (wt) and EGFP‐AR (Thr‐Ala877) expression vectors, the coding sequence of each *AR* cDNA was ligated into multiple cloning sites of the pEGFP‐C1 vector (Clontech, Palo Alto, CA). At 23 h after seeding approximately 2 × 10^4^ cells/100 μl/well onto a multiple‐chamber slide, LNCaP cells were transfected with 50 ng of each AR/pEGFP‐C1 in 0.3 μl FuGeneHD (Promega)/well in a manner similar to the introduction of the *AR* expression vectors. Then, 24 h later, 2.0 × 10^−8^ M of each steroid hormone was administrated to the cells which were incubated for another 24 h. The cells were fixed by 4% paraformaldehyde, and intracellular localization of EGFP‐AR was examined using the Nikon A1 Confocal Microscope System. Nuclei were stained with DAPI.

Statistical analysis {#jcp24906-sec-0012}
--------------------

Data are expressed as means ± SD of four independent experiments, unless otherwise stated. Statistical analysis was carried out using Student\'s *t*‐test (Fig. [1](#jcp24906-fig-0001){ref-type="fig"}C, F, G, and H) or one‐factor ANOVA and Tukey\'s test (Figs. [1](#jcp24906-fig-0001){ref-type="fig"}B, E, I, J, K, 2, 3B, 5, 6A, and 7) (Supplemental Fig. 2, 4A, B and 5).

![The androgen receptor (AR) exclusively mediates *parathyroid hormone‐related protein* gene repression by several steroid hormones in LNCaP cells. (A) Western blotting of AR, estrogen receptor (ER)α, progesterone receptor (PR)‐A and PR‐B proteins in LNCaP, MCF‐7, and T47D cells using AR (H‐280), ERα, and PR (reacted with both isoforms of PR‐A and PR‐B) antibodies. Anti‐α‐tubulin antibody was used as the loading control. (B) *Parathyroid hormone‐related protein* (*PTHrP*) mRNA in LNCaP cells treated with dihydrotestosterone (DHT), 17β‐estradiol (E2), or R5020 was analyzed by quantitative real‐time (qRT)‐PCR. The concentrations of the used hormones were 10^−9^, 10^−8^, and 10^−7^ M, respectively. Data are normalized to *GAPDH* mRNA levels and represented relative to the vehicle (%). ^\*^ *P *\< 0.01 compared with the vehicle. (C--E) Control siRNA (siCT) and *AR* siRNA (siAR) were introduced into the respective LNCaP cells. At 24 h after transfection, *AR* mRNA (C) and protein (D) were analyzed. (C) *AR* mRNA in the transfected LNCaP cells was analyzed by real‐time PCR. Data are normalized to *GAPDH* and represented as the ratio of *AR* mRNA in the siAR groups to that in the siCT groups (%). ^\*^ *P *\< 0.01 compared with siCT. (D) Western blotting with the AR antibody. Anti‐α‐tubulin antibody was used as the loading control. (E) Real‐time PCR assay of *PTHrP* mRNA. LNCaP cells with or without siAR were treated with 10^−7^ M DHT for 24 h. Black and gray bars indicate the effect of vehicle and DHT, respectively. Data are shown relative to the siCT of the vehicle (%). ^\*^ *P *\< 0.01 compared with each vehicle. (F--K) siCT and siRNAs for each *NR* (siERα, siERβ, and siPR) were introduced into the respective LNCaP cells. Data are normalized to *GAPDH* expression. (F--H) At 24 h after transfection, the mRNA expression of *ERα* (F), *ERβ* (G), and *PR* (H) in the LNCaP cells was analyzed by real‐time PCR. Data are presented as ratios relative to siCT (%). ^\*^ *P *\< 0.01 and ^\*\*^ *P *\< 0.05 compared with the siCT lane. (I--K) At 24 h after transfection of each siRNA, LNCaP cells were treated with 10^−7^ M E2 (I, J) or R5020 (K) for another 24 h. Expression of the *PTHrP* gene was analyzed by real‐time PCR. Black and gray bars indicate the results after vehicle and steroid hormone treatment, respectively. Data are shown relative to the vehicle (%). ^\*^ *P *\< 0.01 compared with each vehicle. (B--C and E--K) Data are presented as means ± SD (n = 4).](JCP-230-1594-g001){#jcp24906-fig-0001}

Results {#jcp24906-sec-0013}
=======

Several steroid hormones repressed PTHrP expression in LNCaP cells {#jcp24906-sec-0014}
------------------------------------------------------------------

To explore the effects of E2, DHT, and R5020 on *PTHrP* expression in prostate cancer LNCaP cells, we first examined the cognate NR mRNAs of *ERα, AR*, and *PR* in LNCaP cells by qRT‐PCR. We also analyzed the expression of *NRs* in prostate cancer Rv22 and breast cancer MCF‐7, T47D, and MDA‐MB‐453 cells. The expression of *NRs* was presented relative to that of *GAPDH*. Considerable amounts of *AR* expression were confirmed in both LNCaP and Rv22 cells, and excessive levels were found in the MDA‐MB‐453 cells (Table [1](#jcp24906-tbl-0001){ref-type="table"}). MCF‐7 and T47D cells also expressed *AR* mRNA, but the expression levels seemed notably lower in these cells than in the prostate cancer cells. On the other hand, expression of *ERα* and *PR* was negligible in the LNCaP cells. *ERα* and *PR* expression was recognized only in the breast cancer cell lines (Table [1](#jcp24906-tbl-0001){ref-type="table"}). We found that the amount of *ERβ* mRNA in LNCaP cells was extremely low compared to that of *ERα* in MCF‐7 or LNCaP cells (Table [1](#jcp24906-tbl-0001){ref-type="table"}), although some reports argued that LNCaP cells express fairly abundant amounts of ERβ protein (Lau et al., [2000](#jcp24906-bib-0030){ref-type="ref"}; Bektic et al., [2004](#jcp24906-bib-0004){ref-type="ref"}).

###### 

Expression of *NR* mRNAs in prostate cancer and breast cancer cell lines

                                                Relative expressions toward GAPDH (%)                 
  ------------ ----------------- -------------- --------------------------------------- ------------- --------------
  LNCaP        Prostate cancer   \<0.0          \<0.0                                   100.0 ± 0.7   \<0.0
  Rv22         Prostate cancer   \<0.0          \<0.0                                   60.0 ± 8.2    \<0.0
  MCF‐7        Breast cancer     100.0 ± 6.1    \<0.0                                   14.2 ± 1.0    3.4 ± 0.4
  T47D         Breast cancer     146.9 ± 17.0   0.6 ± 0.1                               30.2 ± 1.0    100.0 ± 11.8
  MDA‐MB‐453   Breast cancer     \<0.0          \<0.0                                   17.8 ± 24.9   \<0.0

ERα and ERβ values are shown relative to the ERα in the MCF‐7 cells 100(%). AR values are shown relative to the AR in the LNCaP cells (%). PR values are shown relative to the PR in the T47D cells (%). Data are expressed as means ± SD of four independent experiments.

© 2015 Wiley Periodicals, Inc.

Using western blotting, we analyzed the expression of the AR, ERα, and two PR isoforms, PR‐A and PR‐B proteins, in LNCaP cells along with MCF‐7 and T47D cells as positive controls. As shown Fig. [1](#jcp24906-fig-0001){ref-type="fig"}A, the LNCaP cells, unlike the other cells, expressed a massive amount of AR, while the expression of ERα and PRs was negligible, demonstrating that the LNCaP cells expressed only AR protein among the NRs examined in this study.

We next investigated the effects of these steroid hormones on *PTHrP* expression. Endogenous *PTHrP* mRNA expression was repressed by 10^−9^ M DHT to 11% of the vehicle (Fig. [1](#jcp24906-fig-0001){ref-type="fig"}B). Higher concentrations of DHT showed further dose‐dependent repression (Fig. [1](#jcp24906-fig-0001){ref-type="fig"}B). Similarly, in the LNCaP cells, E2 and R5020 repressed endogenous *PTHrP* mRNA expression in a dose‐dependent manner (Fig. [1](#jcp24906-fig-0001){ref-type="fig"}B), while the cognate *NR* mRNAs or proteins were minimally expressed in the LNCaP cells.

PTHrP gene repression by steroid hormones was abrogated on knockdown of the AR, but not other NRs {#jcp24906-sec-0015}
-------------------------------------------------------------------------------------------------

To test whether or not the repression of *PTHrP* by the steroid hormones was mediated through the cognate NRs, we performed knockdown of *NR* expression in the LNCaP cells by transfection with siRNA specific to each *NR*. First, we employed *AR*‐specific siRNA, which decreased the *AR* mRNA to 13% (Fig. [1](#jcp24906-fig-0001){ref-type="fig"}C), and the AR protein level dropped to \<10% that of the control (Fig. [1](#jcp24906-fig-0001){ref-type="fig"}D). As shown in Fig. [1](#jcp24906-fig-0001){ref-type="fig"}E, knockdown of the *AR* completely counteracted the DHT‐dependent repression of *PTHrP* expression. These results imply that the AR in the LNCaP cells is required for DHT‐mediated *PTHrP* mRNA repression.

Next, we performed a series of knockdown experiments using siRNAs specific to *ERα* and *PR*. Efficient further knockdown of the scarce expression of each *NR* was confirmed by qRT‐PCR; *ERα* to 32% (Fig. [1](#jcp24906-fig-0001){ref-type="fig"}F), *ERβ* to 43% (Fig. [1](#jcp24906-fig-0001){ref-type="fig"}G) and *PR* to 19% (Fig. [1](#jcp24906-fig-0001){ref-type="fig"}H). Surprisingly, the individual reduction of each *NR* failed to reverse the *PTHrP* repression mediated by the respective cognate hormone (Fig. [1](#jcp24906-fig-0001){ref-type="fig"}I--K), suggesting that the NRs, except for the AR, were dispensable for the steroid hormone‐dependent suppression of the *PTHrP* gene. We then examined whether the AR was involved in the repression of *PTHrP* induced by E2 and R5020. As shown in Fig. [1](#jcp24906-fig-0001){ref-type="fig"}I--K, knockdown of the *AR* completely restored the E2‐ and R5020‐induced reductions in *PTHrP* mRNA, indicating that the AR in LNCaP cells was required for repression of the *PTHrP* gene mediated not only by DHT, but also by E2 and R5020.

Role of the AR in PSA gene activation {#jcp24906-sec-0016}
-------------------------------------

We next focused on the transcriptional regulation of the *PSA* gene as an AR target in the LNCaP cells. Expression of the *PSA* gene was significantly stimulated by DHT in a dose‐dependent manner (Fig. [2](#jcp24906-fig-0002){ref-type="fig"}A), and knockdown of the *AR* completely counteracted the DHT‐dependent activation of *PSA* gene expression (Fig. [2](#jcp24906-fig-0002){ref-type="fig"}D). Subsequently, we investigated the effects of other steroid hormones on *PSA* gene expression. As shown in Fig. [2](#jcp24906-fig-0002){ref-type="fig"}B, C, E, F, and G, E2 and R5020 also stimulated *PSA* gene expression, but further knockdown of their cognate NRs did not abolish their respective stimulatory effects. Nevertheless, as seen in *PTHrP* gene regulation (Fig. [1](#jcp24906-fig-0001){ref-type="fig"}), simultaneous activation of the *PSA* gene by each hormone was completely abolished by single knockdown of the *AR* (Fig. [2](#jcp24906-fig-0002){ref-type="fig"}D--G). These results strongly imply that the AR in the LNCaP cells was solely responsible for *PTHrP* gene repression, as well as the *PSA* gene activation mediated concurrently by the two steroid hormones in addition to DHT. In separate experiments, AR‐driven *PTHrP* and *PSA* gene regulation was confirmed using the AR‐specific antagonist MDV3100 (Scher et al., [2010](#jcp24906-bib-0051){ref-type="ref"}; Ha et al., [2013](#jcp24906-bib-0021){ref-type="ref"}). Co‐treatment of all the used steroid hormones with 10^−5^ M MDV3100 antagonized the gene regulation of *PTHrP* and *PSA* (Supplemental Fig. 2).

![AR as an exclusive mediator of *prostate‐specific antigen* activation by several steroid hormones in LNCaP cells. Levels of *prostate‐specific antigen* (*PSA*) mRNA in LNCaP cells treated with DHT (A, D), E2 (B, E, F), and R5020 (C, G) were analyzed by qRT‐PCR. The concentrations of the hormones were 10^−9^, 10^−8^, and 10^−7^ M for A--C, and 10^−7^ M for D‐G, respectively. (D--G) The effects of siCT and siNRs on *PSA* gene activation are shown. Data are normalized to *GAPDH* expression and presented as means ± SD (n = 4). Data are shown relative to the vehicle (%). ^\*^ *P *\< 0.01 and ^\*\*^ *P *\< 0.05 compared with the vehicle.](JCP-230-1594-g002){#jcp24906-fig-0002}

Several steroid hormones induced nuclear localization of the endogenous AR (Thr‐Ala877) in LNCaP cells {#jcp24906-sec-0017}
------------------------------------------------------------------------------------------------------

Mutation of the AR (Thr‐Ala877) in LNCaP cells was reported to result in the partial loss of the AR\'s ligand specificity and cross‐reaction with several steroid ligands including E2 and progesterone (Veldscholte et al., [1992](#jcp24906-bib-0059){ref-type="ref"}). We analyzed the intracellular localization of the endogenous AR (Thr‐Ala877) by immunocytochemistry. At 24 h after 10^−7 ^M hormone treatment, the LNCaP cells were fixed with 4% paraformaldehyde, followed by immunocytochemistry with AR (H‐280) of which the epitope corresponds to amino acids 91--370 of human AR. Consistent with a previous study (Ni et al., [2013](#jcp24906-bib-0042){ref-type="ref"}), we noticed that nuclear, but not cytoplasmic staining, of the AR (Thr‐Ala877) was a characteristic feature, irrespective of the hormone status in the LNCaP cells. In vehicle‐treated LNCaP cells, the nuclear AR (Thr‐Ala877) was observed at a low frequency (Fig. [3](#jcp24906-fig-0003){ref-type="fig"}A, arrow). In contrast, the AR (Thr‐Ala877) treated with DHT showed well‐demarcated nuclear localization with notably stronger signals at a higher frequency, which was reproducibly observed in both the E2‐ and R5020‐treated cells (Fig. [3](#jcp24906-fig-0003){ref-type="fig"}A). Real‐time PCR (Fig. [3](#jcp24906-fig-0003){ref-type="fig"}B) and western blotting using whole cell protein (Fig. [3](#jcp24906-fig-0003){ref-type="fig"}C) showed that these three hormones actually enhanced AR expression. Western blotting using fractionated proteins revealed that these hormones increased the amount of AR (Thr‐Ala877) in the nuclear fraction (Fig. [3](#jcp24906-fig-0003){ref-type="fig"}C). Notably, even in vehicle‐treated LNCaP cells, AR (Thr‐Ala877) was present both in cytoplasm and nucleus, indicating hormone‐independent nuclear localization of the mutant AR (Thr‐Ala877) (Fig. [3](#jcp24906-fig-0003){ref-type="fig"}C). Western blotting (Fig. [3](#jcp24906-fig-0003){ref-type="fig"}C) seemed to conform to those of immunocytochemistry (Fig. [3](#jcp24906-fig-0003){ref-type="fig"}A). The hormone‐dependent nuclear accumulation and the hormone‐independent nuclear localization of the endogenous AR (Thr‐Ala877) in LNCaP was reconfirmed with another AR antibody, AR (C‐19), whose epitope corresponds to amino acids 869--919 of AR of human origin (Supplemental Fig. 3).

![Nuclear translocation of the AR triggered by various steroid hormones in LNCaP cells. (A) Immunocytochemical analysis with AR antibody, AR (H‐280) was performed. At 24 h after treatment with each steroid hormone, LNCaP cells fixed by 4% paraformaldehyde were incubated with the anti‐AR antibody. Each hormone was added at a dose of 10^−7^ M. (Upper panel) AR visualized with the Alexa 546‐labeled secondary antibody (red). (Middle panel) Nuclear staining with DAPI (blue). (Lower panel) Merged images. Modest staining of the nuclear AR, even in the absence of hormones, is indicated by the arrow. Scale bar = 10 μm. (B) *AR* mRNA in LNCaP cells treated with DHT, E2, or R5020 was analyzed by quantitative real‐time PCR. The concentrations of the used hormones were 10^−7 ^M, respectively. Data are normalized to *GAPDH* mRNA levels and represented relative to the vehicle (%). ^\*^ *P *\< 0.01 compared with the vehicle. (C) Western blotting of AR (H‐280) using fractionated LNCaP cells protein was performed. Anti‐α‐tubulin antibody was used as the loading control for whole protein (WP). Anti‐α‐tubulin antibody was used as the cell fraction control for cytoplasm protein (CP) and anti‐Pol II antibody were used as that for nuclear protein (NP), respectively. We also used anti‐Lamin A/C antibody as another NP fraction control (Supplemental Fig. 7C). V, D, E, and R indicated Vehicle, DHT, E2 and R5020, respectively.](JCP-230-1594-g003){#jcp24906-fig-0003}

These results indicate that the three hormones used in this study provoked expression and nuclear translocation of the AR (Thr‐Ala877) in parallel. However, treatment of LNCaP cells with atRA had no influence on the expression of *PTHrP* or *PSA*, and no nuclear localization of the AR (Thr‐Ala877) was convincingly confirmed (Supplemental Fig. 4A--C).

Exhaustive gene expression profiles regulated by cross‐reactive hormones via AR (Thr‐Ala877) {#jcp24906-sec-0018}
--------------------------------------------------------------------------------------------

To examine whether hormonal cross‐reactivity mediated by the AR (Thr‐Ala877) was widespread in the LNCaP cells, we performed cDNA microarray analysis. The comprehensive gene expression profile was determined by assessing the total RNA from the LNCaP cells after transfection with either control siRNA (siCT) or siRNA for AR (siAR) followed by 10^−7 ^M of DHT, E2, or R5020 administration (GEO accession number: GSE58615). The signals derived from each probe were expressed as the signal/median value divided by the median value of all the probes, and the fold increment of the activities after each hormone treatment was calculated. To isolate the putative target genes of the AR (Thr‐Ala877) stimulated by each hormone, we focused on the probes whose values were drastically changed by hormone administration using siCT (≥5.0 or ≤0.2) with minimal changes in siAR (1.0--2.0 and 0.75--1.0). As shown in Fig. [4](#jcp24906-fig-0004){ref-type="fig"}A, 547, 426, and 394 probes were target probes for the DHT‐, E2‐, and R5020‐AR, respectively. Overall, 51.9% and 49.5% of the DHT‐AR target genes were shared with the E2‐AR and R5020‐AR targets, respectively. Similarly, 66.7% and 68.3% of the E2‐AR target genes were shared with the DHT‐AR and R5020‐AR probes, and 68.8% and 73.9% of the R5020‐AR target genes overlapped with the DHT‐AR and E2‐AR probes, respectively. These results led us to conclude that more than half of the genes were common targets among the AR (Thr‐Ala877) responders regulated by the three hormones (Fig. [4](#jcp24906-fig-0004){ref-type="fig"}B).

![Comparison of DHT‐AR, E2‐AR, and R5020‐AR target gene profiles in LNCaP cells. Microarray analysis was performed to investigate the exhaustive target gene profiles of DHT, E2, and R5020 via the AR (Thr‐Ala877) in LNCaP cells. (A) The proportion of common target probes between each group is listed. The percentage and number of probes in each group is shown. (B) Venn diagram showing the distribution of the DHT‐AR (black), E2‐AR (red), and R5020‐AR (blue) target probes. The numbers outside the Venn diagram indicate the total number of each probe and those inside the Venn diagram indicate the number of probes in each group.](JCP-230-1594-g004){#jcp24906-fig-0004}

To demonstrate the interaction of AR with some cofactors, we administrated trichostatin A (TSA) as an HDAC inhibitor. TSA is expected to abolish gene repression if HDACs are recruited to down‐regulate *PTHrP* expression. On the other hand, TSA is also reported to inhibit hormone‐dependent recruitment of co‐activators such as p300 and SRC1 in gene activation (Welsbie et al., [2009](#jcp24906-bib-0061){ref-type="ref"}). Thus, TSA might cancel hormone‐dependent *PSA* gene activation. As shown in Fig. [5](#jcp24906-fig-0005){ref-type="fig"}, *PTHrP* gene repression and *PSA* gene activation both mediated by the three hormones in LNCaP cells were lost in common after TSA treatment, implying that the co‐factors such as HDACs for *PTHrP* repression and, p300 and SRC1 for *PSA* activation were recruited to the hormone‐ and AR‐dependent transcription machinery.

![TSA commonly abandoned DHT, E2, and R5020 dependent repression of *PTHrP* as well as activation of *PSA*. The concentration of DHT, E2, and R5020 was 10^−7 ^M. TSA was used concomitantly at the dose of 10^−6^ M for 24 h. The expression levels of *PTHrP* (A) and *PSA* mRNAs (B) in LNCaP cells were analyzed by quantitative real‐time PCR. Black and gray bars indicate treatment of Vehicle and TSA, respectively with each steroid hormone. ^\*^ *P *\< 0.01 compared with the vehicle.](JCP-230-1594-g005){#jcp24906-fig-0005}

E2‐dependent gene regulation by the AR was caused not by the mutation of the AR (Thr‐Ala877) {#jcp24906-sec-0019}
--------------------------------------------------------------------------------------------

To verify whether the skewed crosstalk of the AR (Thr‐Ala877) with the used steroid hormones originated from its LBD mutation, we expressed AR (Thr‐Ala877) and AR (wt) separately in the LNCaP cells wherein we confirmed the endogenous existence of the mutated AR (Thr‐Ala877) (data not shown). We then performed a luciferase reporter assay using the canonical and widely appreciated ARE (AR response element; GGAACAgtaTGTTCT) (Roche et al., [1992](#jcp24906-bib-0050){ref-type="ref"}) along with either of the AR expression vectors in the LNCaP cells. This ARE sequence is closely related to the native ARE in the 5\' flanking region of the *PSA* gene (Cleutjens et al., [1996](#jcp24906-bib-0009){ref-type="ref"}) and is considered to represent the *bona fide* AREs in various cell types (Roche et al., [1992](#jcp24906-bib-0050){ref-type="ref"}) with high binding affinity for the AR and high transcription activity by means of hormone‐stimulated AR.

As shown in Fig. [6](#jcp24906-fig-0006){ref-type="fig"}A, DHT treatment in the absence of exogenous AR hardly enhanced ARE promoter activity. In contrast, when either the AR (wt) or AR (Thr‐Ala877) was expressed, we observed marked reporter activation by DHT in a dose‐dependent manner. Treatment with 10^−9^, 10^−8^, and 10^−7^ M DHT conferred a 6.8‐, 8.7‐, and 10.5‐fold stimulation, respectively on the reporter activity after co‐transfection with the AR (wt) in the LNCaP cells, while co‐transfection with the AR (Thr‐Ala877) yielded weaker but significantly enhanced reporter activity (Fig. [6](#jcp24906-fig-0006){ref-type="fig"}A). In this experiment, disproportionally excessive amounts of the ARE were co‐introduced in our reporter assay (Fig. [6](#jcp24906-fig-0006){ref-type="fig"}A). We reasoned that the reporter activity in response to DHT failed to increase in the presence of the endogenous AR (Thr‐Ala877) alone, probably because of depletion or squelching of the transcriptional coregulators after these procedures (Fig. [6](#jcp24906-fig-0006){ref-type="fig"}A).

![Steroid hormone‐dependent promoter activation and nuclear translocation of the exogenously introduced AR (wild‐type) and AR (Thr‐Ala877) in LNCaP cells. (A) The plasmid pcDNA3.1‐based expression vectors, AR (wild‐type; wt) and AR (Thr‐Ala877), as well as an empty vector, were introduced into LNCaP cells together with the ARE × 3/pGL4‐TK reporter. At 24 h after transfection, the cells were treated with 10^−9^, 10^−8^, and 10^−7^ M of DHT, E2, and R5020, respectively for 24 h followed by luciferase assay. The blue, red, and green lines in each graph denote the response induced by the introduction of pcDNA3.1, AR (wt), and AR (Thr‐Ala877), respectively. Data are expressed as fold changes relative to the vehicle. ^\*^ *P *\< 0.01 compared with the vehicle. (B--E) At 24 h after transfection with enhanced green fluorescent protein (EGFP) (B), EGFP‐AR (Thr‐Ala877) (C), or EGFP‐AR (wt) (D and E), the indicated steroid hormones (10^−7^ M) were included for another 24 h. In E, 24 h before transfection with EGFP‐AR (wt), AR siRNA was introduced concurrently with cell seeding to knockdown the endogenous mutant AR (Thr‐Ala877). (Upper panels) EGFP (B), EGFP‐AR (Thr‐Ala877) (C), and EGFP‐AR (wt) (D and E) (green). (Middle panels) DAPI (blue). (Lower panels) Merged images. Note that the stained cells in each upper panel and the double stained cells in each lower panel originated from the DAPI‐positive cells shown in the middle panels, reflecting a transfectional efficiency of around 5%. Scale bar = 10 μm.](JCP-230-1594-g006){#jcp24906-fig-0006}

We then examined the effects of other steroid hormones on the ARE reporter activity after separate introduction of each AR. Similar to DHT, we observed that both the AR (wt) and AR (Thr‐Ala877) noticeably responded to E2 in a dose‐dependent manner.

In response to the progesterone agonist R5020, the AR (Thr‐Ala877), but not the AR (wt), stimulated the reporter activity in a dose‐dependent manner (Fig. [6](#jcp24906-fig-0006){ref-type="fig"}A), implying crosstalk between R5020 and the AR (Thr‐Ala877), as reported previously (Veldscholte et al., [1992](#jcp24906-bib-0059){ref-type="ref"}). We therefore assumed that the AR (Thr‐Ala877), unlike the AR (wt), responds to R5020.

Nuclear localization of the exogenous EGFP‐AR (wt) after E2 or DHT treatment of LNCaP cells {#jcp24906-sec-0020}
-------------------------------------------------------------------------------------------

In order to prove the responsibility of not only the AR (Thr‐Ala877), but also the AR (wt) for the skewed crosstalk of the steroid hormones, we analyzed the influence of each steroid hormone on the subcellular localization of the AR (wt) in the LNCaP cells. We utilized the EGFP‐AR (wt) or EGFP‐AR (Thr‐Ala877) fusion protein expression vector to visualize intracellular localization of either type of AR in the LNCaP cells with or without steroid hormones. At 24 h after introducing one of the EGFP‐ARs, we added 10^−7^ M of each steroid hormone for another 24 h and then performed confocal fluorescence microscopy analysis. The hormones used in this experiment had no influence on the intracellular behavior of EGFP when the AR was absent from the transfection (Fig. [6](#jcp24906-fig-0006){ref-type="fig"}B). Remarkably, treatment of the LNCaP cells with vehicle alone exhibited distinct cytoplasmic retention of the exogenously introduced EGFP‐AR (wt) (Fig. [6](#jcp24906-fig-0006){ref-type="fig"}D), while the extrinsic EGFR‐AR (Thr‐Ala877) remained exclusively in the nucleus in this condition and continued remaining in the nucleus after each hormone treatment (Fig. [6](#jcp24906-fig-0006){ref-type="fig"}C). Such AR (Thr‐Ala877) behavior was reminiscent of the endogenous nuclear AR (Thr‐Ala877) retention pattern observed irrespective of hormonal status (Fig. [3](#jcp24906-fig-0003){ref-type="fig"}). Molecular mechanisms of this AR (Thr‐Ala877) behavior are still unclear. The AR Thr‐Ala877 mutation might affect the interdomain interaction of AR or change its interaction with some import factor(s). Most importantly, E2 treatment forced the cytoplasmic EGFP‐AR (wt) to move into the nuclear compartment as completely as with the DHT treatment (Fig. [6](#jcp24906-fig-0006){ref-type="fig"}D). R5020 also seemed to convert the intracellular EGFP‐AR (wt) in the nuclear compartment. Treatment with atRA had no influence on the localization of the EGFP‐AR (wt) (Supplemental Fig. 4D).

To examine whether the endogenous AR (Thr‐Ala877) affects the subcellular localization of the introduced AR (wt), we expressed the EGFP‐AR (wt) in the LNCaP cells after knockdown of the endogenous AR (Thr‐Ala877) with siRNA. As shown in Fig. [6](#jcp24906-fig-0006){ref-type="fig"}E, R5020 changed the EGFP‐AR (wt) location from nuclear (Fig. [6](#jcp24906-fig-0006){ref-type="fig"}D) to both compartments (Fig. [6](#jcp24906-fig-0006){ref-type="fig"}E), implying that the endogenous AR (Thr‐Ala877), unless silenced, somehow interfered with the cytoplasmic retention of the introduced EGFP‐AR (wt) (Fig. [6](#jcp24906-fig-0006){ref-type="fig"}D). However, addition of E2 or DHT after introduction of the EGFP‐AR (wt) into the AR (Thr‐Ala877)‐disrupted cells essentially did not alter EGFP‐AR (wt) nuclear localization (Fig. [6](#jcp24906-fig-0006){ref-type="fig"}E).

Along with the reporter gene assay (Fig. [6](#jcp24906-fig-0006){ref-type="fig"}A), these subcellular microscopic experiments strongly validate our hypothesis that E2, as well as DHT, utilize the AR (wt) to regulate the AR (wt)‐responsive genes in LNCaP cells independently of the AR mutation, such as AR (Thr‐Ala877).

MDA‐MB‐453 cells, unlike LNCaP cells, did not exhibit E2‐dependent ARE promoter activation via the wild‐type AR {#jcp24906-sec-0021}
---------------------------------------------------------------------------------------------------------------

Of note, our concern regarding the subtle contamination of any used hormones with other hormone reagents was eliminated by the experiment using the MDA‐MB‐453 breast cancer cell line, which is ERα‐negative but AR‐positive. Reportedly, the AR in MDA‐MB‐453 cells acquired a substitution of Glu‐His865 in its LBD, resulting in the altered sensitivity to DHT and medroxyprogesterone acetate, but not to non‐androgenic ligands (Moore et al., [2012](#jcp24906-bib-0040){ref-type="ref"}). We confirmed that expression of the *FKBP51* gene, a DHT target in the MDA‐MB‐453 cells, was stimulated by DHT in these cells, but not by E2 or R5020 (Supplemental Fig. 5), validating the purity of our hormone preparations.

We next employed the MDA‐MB‐453 cells for the ARE reporter assay (Fig. [7](#jcp24906-fig-0007){ref-type="fig"}A). In these cells with no overexpression of AR, three hormones including DHT failed to stimulate ARE promoter activity. However, when excessive amounts of the AR (wt) were exogenously introduced to counteract the relative lack of AR over the massive level of the ARE, the luciferase activity driven by the ARE‐containing reporter gene was stimulated by DHT, but again not by E2 or R5020 (Fig. [7](#jcp24906-fig-0007){ref-type="fig"}A). These results indicate that the MDA‐MB‐453 cells, unlike the LNCaP cells, failed to stimulate E2‐dependent reporter activity via the AR (wt). On the other hand, when the AR (Thr‐Ala877) alone was co‐transfected, E2 and R5020, in addition to DHT, gained the ability to stimulate the promoter activities (Fig. [7](#jcp24906-fig-0007){ref-type="fig"}A), again reproducing the partial loss of the AR\'s ligand specificity after the substitution of Thr‐Ala877 (Veldscholte et al., [1992](#jcp24906-bib-0059){ref-type="ref"}; Grigoryev et al., [2000](#jcp24906-bib-0020){ref-type="ref"}), even in the MDA‐MB‐453 cells.

![Steroid hormone‐dependent activation of the AR response element containing reporter activity in other prostate and breast cancer cells. Luciferase assay after introducing the empty pcDNA3.1, AR (wt) expression vector, or AR (Thr‐Ala877) expression vector together with the AR response element (ARE) × 3/pGL4‐TK vector in MDA‐MB‐453 (A), Rv22 (B), and MCF‐7 (C) cells. Cells were treated and assays were performed as described in Fig. [5](#jcp24906-fig-0005){ref-type="fig"}. The black, gray, and white lines show the values for pcDNA3.1, AR (wt), and AR (Thr‐Ala877), respectively. Data are expressed as fold changes relative to the vehicle. ^\*^ *P *\< 0.01 and *^\*\*^P *\< 0.05 compared with pcDNA3.1 in each group, respectively.](JCP-230-1594-g007){#jcp24906-fig-0007}

MCF‐7 and Rv22 cells, like the LNCaP cells, showed DHT‐ and E2‐dependent ARE promoter activation via the wild‐type AR {#jcp24906-sec-0022}
---------------------------------------------------------------------------------------------------------------------

To verify whether or not the E2‐dependent ARE promoter activation via the wt AR was an LNCaP cell‐specific event, we carried out the ARE reporter assay in prostate cancer Rv22 cells and breast cancer MCF‐7 cells. Interestingly, in both cell lines, unlike in the MDA‐MB‐453 cells, the exogenous AR (wt) enhanced not only the DHT‐, but also the E2‐dependent ARE promoter activities, implying that these cells exhibited distorted interactions between E2 and AR (wt) signaling (Fig. [7](#jcp24906-fig-0007){ref-type="fig"}B, C). Nonetheless, R5020 had no effect (Fig. [7](#jcp24906-fig-0007){ref-type="fig"}B, C). Therefore, the behavior of the extrinsic AR (wt) in response to E2 or R5020 was highly similar among the Rv22, MCF‐7, and LNCaP cells (Figs. [6](#jcp24906-fig-0006){ref-type="fig"}A and 7B, C). On the other hand, when the AR (Thr‐Ala877) was co‐transfected, E2 and R5020 in addition to DHT in the MCF‐7 cells (Fig. [7](#jcp24906-fig-0007){ref-type="fig"}C), but only R5020 in the Rv22 cells (Fig. [7](#jcp24906-fig-0007){ref-type="fig"}B), gained the ability to stimulate promoter activity. These results might imply that the partial loss of the AR\'s ligand specificity due to the AR (Thr‐Ala877) mutation occurred in a non‐cell‐specific manner. Next, we found that the Rv22 cells had the known AR mutation of His‐Tyr874 in their LBD (data not shown), which was previously reported to cross‐react with E2 and progesterone (Taplin et al., [1995](#jcp24906-bib-0057){ref-type="ref"}; Duff and McEwan, [2005](#jcp24906-bib-0011){ref-type="ref"}), but we confirmed that the AR in the MCF‐7 cells had no mutation in either allele (data not shown).

Taken together, the cross‐reactive recognition of the AR (wt) by both DHT and E2 was rather widely conserved among several cell lines (Fig. [8](#jcp24906-fig-0008){ref-type="fig"}).

![Diverse interactions of the AR with the steroidal ligands in several cell lines. (Left) Previous reports by others postulated that the endogenous AR (Thr‐Ala877) upregulated or downregulated the AR target genes mediated not only by DHT, but also by E2 and R5020 in LNCaP cells. (Middle) In addition, we found that the extrinsic wild‐type AR overexpressed in the LNCaP cells responded to E2. Even in the Rv22 and MCF‐7 cells, the exogenous AR (wt) exhibited a skewed crosstalk with E2 in ARE‐containing reporter gene activity. (Right) In MDA‐MB‐453 cells, the endogenous AR (Glu‐His865), as well as the exogenous AR (wt), responded only to DHT, while the exogenous AR (Thr‐Ala877) maintained its responses to E2 and R5020. \*Endo AR (Glu‐His865) regulates the endogenous *FKBP51* gene. Exo AR (wt) and Exo AR (Thr‐Ala877) regulate the exogenous ARE‐containing reporter gene. Throughout the figure, "Exo" denotes "exogenously introduced" and "Endo" denotes "endogenously expressed".](JCP-230-1594-g008){#jcp24906-fig-0008}

Discussion {#jcp24906-sec-0023}
==========

To further extend our previous finding of ligand‐dependent repression of *PTHrP* via the aberrant DHT‐ERα axis in MCF‐7 cells (Kajitani et al., [2011](#jcp24906-bib-0026){ref-type="ref"}), we performed a series of experiments to unravel whether such a distorted ligand‐NR interaction also occurs in steroid hormone‐dependent prostate LNCaP cells. In this study, we confirmed the physiological signaling pathway between wt AR and E2 in LNCaP cells as well as other sex hormone‐sensitive cells such as Rv22, and MCF‐7 cells.

To analyze the interaction between hormones and either AR (Thr‐Ala877) or AR (wt) in the LNCaP cells, we employed intracellular localization analysis. As expected, E2 along with DHT clearly brought about nuclear retention of both the extrinsic and intrinsic ARs (Thr‐Ala877) (Figs. [3](#jcp24906-fig-0003){ref-type="fig"} and [6](#jcp24906-fig-0006){ref-type="fig"}C). Moreover, we found that E2 markedly promoted nuclear translocation of the EGFP‐AR (wt) when exogenously added or re‐introduced after knockdown of the endogenous AR (Thr‐Ala877) (Fig. [6](#jcp24906-fig-0006){ref-type="fig"}D, E). To our knowledge, this is the first report visualizing wt‐AR nuclear translocation after E2 treatment in hormone‐sensitive cultured cells expressing no functional ERα. Taken together with the subsequent reporter assay, these results demonstrated that the AR (Thr‐Ala877) did not necessarily contribute to the E2 crosstalk and that the AR (wt) alone conferred skewing of the E2 response (Fig. [6](#jcp24906-fig-0006){ref-type="fig"}A).

In this scenario, we assumed that the contribution of the interaction between the extrinsic AR (wt) and the endogenous AR (Thr‐Ala877) on the effect of each hormone is negligible. As shown in the AR immunoblot (Supplemental Fig. 6), the total amount of each AR reached 2‐fold that of the endogenous AR (Thr‐Ala877) (Supplemental Fig. 6, pcDNA3.1 lane) under an estimated transfectional efficiency of 5% (Fig. [6](#jcp24906-fig-0006){ref-type="fig"}B--E). This indicates that each transfectant expressing the introduced gene was under the influence of either type of the co‐introduced AR of approximately 20‐fold higher abundance compared with the endogenous AR (Thr‐Ala877). Last but not least, MCF‐7 cells with endogenous expression of only the wt AR exhibited similarly aberrant ARE‐reporter activation by E2 when extrinsic AR (wt) was introduced (Fig. [7](#jcp24906-fig-0007){ref-type="fig"}C). These observations strongly underpin our hypothesis that the aberrant crosstalk driven by E2 was exclusively elicited through activation of the *bona fide* AR (wt).

In contrast, unlike E2, R5020 did not affect the ARE‐mediated reporter activity when the AR (wt) was exogenously overexpressed (Fig. [6](#jcp24906-fig-0006){ref-type="fig"}A, red line on R5020 graph). Notwithstanding, R5020, like E2, shifted the introduced EGFP‐AR (wt) from the cytoplasm to the nucleus (Fig. [6](#jcp24906-fig-0006){ref-type="fig"}D). However, when EGFP‐AR (wt) was re‐introduced after silencing the endogenous AR (Thr‐Ala877) expression (Fig. [6](#jcp24906-fig-0006){ref-type="fig"}E), R5020 selectively conferred both cytoplasmic and nuclear re‐distribution to the EGFP‐AR (wt), while its nuclear distribution in the E2‐treated cells was unaltered. It is tempting to speculate from these observations that the intranuclear AR retention was necessary but not sufficient for the subsequent hormonal responses. Our results showing that the AR (Thr‐Ala877) was constitutively present within the nucleus even in the absence of added hormones (Fig. [6](#jcp24906-fig-0006){ref-type="fig"}C) support this contention.

Taken together, it can be considered that the aberrant E2‐AR (wt) signaling observed in the LNCaP cells mirrors our previous finding that the endogenous ERα, but not the AR which was otherwise functional in MCF‐7 cells, mediated DHT‐induced *PTHrP* gene repression (Kajitani et al., [2011](#jcp24906-bib-0026){ref-type="ref"}). However, the underlying mechanism in such an intricate mutual crosstalk remains unknown.

Furthermore, our experiments using TSA revealed that DHT, E2 and R5020 commonly recruited HDAC‐corepressor complexes and coactivators to PTHrP and PSA genes, respectively, in LNCaP cells (Fig. [5](#jcp24906-fig-0005){ref-type="fig"}). Of note, the comprehensive expression profile of the genes located downstream of the AR (Thr‐Ala877) and regulated by either of the three steroid hormones, DHT, E2, or R5020, revealed that more than half but not all genes overlapped in the LNCaP cells (Fig. [4](#jcp24906-fig-0004){ref-type="fig"}). Such non‐overlapping regulation suggests a substitute for the AR (Thr‐Ala877) that is capable of mediating E2‐ or R5020‐specific gene regulation. The ERβ was reported to be expressed in LNCaP cells (Lau et al., [2000](#jcp24906-bib-0030){ref-type="ref"}; Bektic et al., [2004](#jcp24906-bib-0004){ref-type="ref"}) or a membrane form(s) of the unknown receptors might be involved in this process. On the other hand, we realized that even the *PTHrP* or *PSA* genes were not selected as overlapping candidates under our stringent criteria (not shown), implying that the actual numbers of the target genes commonly regulated by these hormones might be considerably underestimated. In this sense, we consider it reasonable to use the canonical, but not gene‐specific ARE as a consensus AR target sequence in our reporter assays.

The recent development of chromatin immunoprecipitation analysis by genome‐wide techniques revealed unforeseen illegitimate interactions between NRs and versatile chromatinized DNA sequences, but such concepts were invariably based on the presumption that the corresponding cognate NR is faithfully expressed for its authentic ligand. For instance, inhibition of the E2‐ERα‐dependent gene regulatory axis by dexamethasone (Dex) has been rigorously studied in MCF‐7 cells (Karmakar et al., [2013](#jcp24906-bib-0027){ref-type="ref"}). In other murine mammary cell lines, Dex‐GR (glucocorticoid receptor) changed the DNA accessibility of the E2‐ERα complex, resulting in its binding to novel specific sites (Miranda et al., [2013](#jcp24906-bib-0037){ref-type="ref"}). In the MDA‐MB‐453 cells, which are ERα‐negative but AR‐positive, DHT‐AR signaling hijacked the E2‐ERα cistrome (Robinson et al., [2011](#jcp24906-bib-0049){ref-type="ref"}). As such, it is possible that reciprocal interactions between the liganded NRs resulted in occasional intricate crosstalk.

In addition, our observation that not only the LNCaP cells, but also the AR (wt)‐expressing MCF‐7 and Rv22 cells, exhibited E2‐mediated regulation through the ARE‐containing luciferase reporter (Figs. [6](#jcp24906-fig-0006){ref-type="fig"}A, 7B and C) strongly suggests that the AR (wt) interacted directly or indirectly with E2 in certain sex hormone‐responsive cancer cells. Regardless, this straightforward hypothesis is very hard to prove in living cells. Reports on classical cloning of NRs, especially homodimer‐requiring species, have often described the ambiguous ligand selectivity of these NRs (Lubahn et al., [1988](#jcp24906-bib-0036){ref-type="ref"}). Nonetheless, unlike the present study, such "cross‐reactivity" was usually found when ligand concentrations were at supra‐physiological levels.

For the distortions observed in this study to occur at least in some cancer cells but not in others, the following predispositions might be required: a security switch for steroid hormones such as 11β‐hydroxysteroid dehydrogenase 2, which inactivates cortisol in aldosterone target cells (Arriza et al., [1987](#jcp24906-bib-0002){ref-type="ref"}; Funder et al., [1988](#jcp24906-bib-0015){ref-type="ref"}; Fuller et al., [2012](#jcp24906-bib-0014){ref-type="ref"}); or an alteration of the enzymatic activity involving the intratumoral conversion of steroidal substances (Mohler et al., [2011](#jcp24906-bib-0039){ref-type="ref"}). Recently, germline polymorphisms in the *CYP1B1, SULT2B1, COMT, NQO1*, and *NQO2* genes, which play roles in multiple estrogen metabolism pathways, were reported to be closely associated with prostate cancer progression (Levesque et al., [2014](#jcp24906-bib-0031){ref-type="ref"}). Further, a history of anti‐hormonal therapies might affect the repertoire of NR binding (Mitsiades, [2013](#jcp24906-bib-0038){ref-type="ref"}).

In summary, we identified a novel regulatory mechanism(s) by which the AR and steroid hormones closely interact with each other in several hormone‐sensitive cancer cell lines. In versatile cells, the AR (wt) accepts E2 as an aberrant ligand and regulates *PTHrP* and *PSA* gene expression regardless of the mutation in its LBD. We successfully demonstrated by fluorescence analysis a probable in vivo interaction between E2 and both the AR (wt) and AR (Thr‐Ala877). We speculate the existence of unknown regulatory mechanistic links between the AR signaling axis and E2 in LNCaP cells and other sex hormone‐responsive cancer cells (Fig. [8](#jcp24906-fig-0008){ref-type="fig"}), and revealing these will be a novel finding. It is desirable to develop drugs targeting such cell‐type‐specific crosstalk between sex hormones with the ability to overcome anti‐hormone resistance in certain types of prostate as well as breast cancers.
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